Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Effects of a fermented milk product containing Bifidobacterium lactis DN173010 in IBS

 

 

 

 

Aliment Pharmacol Ther. 2008 Sep 17. [Epub ahead of print]

 

Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.

 

Agrawal A, A Houghton L, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, J Whorwell P. Neurogastroenterology Unit, Translational Medicine - GI Sciences, University of Manchester, Wythenshawe Hospital, Manchester, M23 9LT, UK.

 

 

Background: A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS) which is more common in patients with constipation, especially those with delayed transit.

 

Aim: To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173-010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation.

 

Methods: A single centre, randomised, double blind, controlled, parallel group study in which patients consumed the test or control product for 4 weeks. Distension, orocaecal and colonic transit, and IBS symptoms were assessed on an intention-to-treat population of 34 patients.

 

Results: Compared with control, the test product resulted in a significant reduction in the percentage change in maximal distension (median difference - 39%, 95%CI (-78, -5); p=0.02) and a trend towards reduced mean distension during the day (-1.52cm (-3.33, 0.39); p=0.096). An acceleration of orocaecal (-1.2hrs (-2.3,0);p=0.049) as well as colonic (-12.2hrs (-22.8,-1.6);p=0.026) transit was observed and overall symptom severity (-0.5 (-1.0,-0.05);p=0.032) also improved.

 

Conclusions: This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.

 

PMID: 18801055 [PubMed - as supplied by publisher]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:11}

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner